alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
(Reap. Dec. 10653)

Entry Nos. 16318; 19488.

#### J. C. Penney Purchasing Corp. *v.*United States

(Decided December 23, 1963)

*■Sharretts, Paley & Carter*for tbe plaintiff.

*John W. Douglas,*Assistant Attorney General, for tbe defendant.

Ford, Judge:

The two appeals for reappraisement listed above have been submitted for decision upon the following stipulation of counsel for the parties hereto:

> IT IS HEREBY STIPULATED AND AGREED by and between counsel for the respective parties hereto that tbe merchandise marked A and initialed WDS by Examiner William D. Slyne on tbe invoices accompanying tbe entries covered by tbe above named appeals for reappraisement consists of rayon fabric and was exported to tbe United States in 1960.

> IT IS FURTHER STIPULATED AND AGREED that on tbe dates of exportation of said merchandise to tbe United States, tbe price at tbe time of exportation at which such or similar merchandise was freely sold or, in tbe absence of sales, offered for sale in the principal markets of tbe country of exportation, in the usual wholesale quantities and in tbe ordinary course of trade, for exportation to tbe United States, including tbe cost of all containers and coverings of whatever nature and all other expenses incidental to placing the merchandise in condition, packed ready for shipment to tbe United States was $0,575 per yard, net, packed.

> IT IS FURTHER STIPULATED AND AGREED that all of tbe merchandise covered by all of the appeals for reappraisement tbe subject of this stipulation is not identified in tbe final list published by tbe Secretary of tbe Treasury pursuant to tbe Customs Simplification Act of 1956, T.D. 54521.

> IT IS FURTHER STIPULATED AND AGREED that these appeals be submitted on this stipulation, said appeals being limited to the merchandise marked A as aforesaid.

Accepting this stipulation as a statement of facts, I find that the involved merchandise, marked “A” and initialed WDS on the in*392voices by Examiner William D. Slyne, is not listed on the final list oí articles published in T.D. 54521, effective February 27, 1958, and that export value, as that value is defined in section 402(b) of the-Tariff Act of 1930, as amended by the Customs Simplification Act of 1956, T.D. 54165, and T.D. 54521, effective February 27, 1958, is-the proper basis for the determination of the value of the merchandise here involved, and I find and hold that such statutory value is $0,575-per yard, net, packed.

Judgment will be entered accordingly.
# C_2015389EN.01006401.xml

| 23.11.2015 | EN | Official Journal of the European Union | C 389/64 |
| --- | --- | --- | --- |

23.11.2015

EN

Official Journal of the European Union

C 389/64

---

Action brought on 25 September 2015 — Aldi v OHIM — Rouard (GOURMET)

(Case T-572/15)

(2015/C 389/72)

Language in which the application was lodged: German

Parties

Parties

Applicant: Aldi GmbH & Co. KG (Mülheim an der Ruhr, Germany) (represented by: C. Fürsen und N. Bertram, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM)

Defendant:

Other party to the proceedings before the Board of Appeal: Pierre-André Rouard (Madrid, Spain)

Other party to the proceedings before the Board of Appeal:

Details of the proceedings before OHIM

Details of the proceedings before OHIM

Proprietor of the trade mark at issue: Applicant

Proprietor of the trade mark at issue:

Trade mark at issue: Community figurative mark with the word element ‘GOURMET’ — Application No 10 509 446

Trade mark at issue:

Procedure before OHIM: Opposition proceedings

Procedure before OHIM:

Contested decision: Decision of the Fourth Board of Appeal of OHIM of 24 July 2015 in Case R 1985/2013-4

Contested decision:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | annul the contested decision; |
| --- | --- |

—

annul the contested decision;

| — | order OHIM to pay the costs. |
| --- | --- |

—

order OHIM to pay the costs.

Pleas in law

Pleas in law

| — | Infringement of Article 63 of Regulation No 207/2009 in conjunction with Rule 20(7) of Regulation No 2868/95; |
| --- | --- |

—

Infringement of Article 63 of Regulation No 207/2009 in conjunction with Rule 20(7) of Regulation No 2868/95;

| — | Infringement of Article 8(1)(b) of Regulation No 207/2009. |
| --- | --- |

—

Infringement of Article 8(1)(b) of Regulation No 207/2009.

---
Document

        



Exhibit 10.57


AMENDMENT NO. 1 TO
MASTER MANUFACTURING SERVICES AND SUPPLY AGREEMENT


This Amendment No. 1 to Master Manufacturing Services and Supply Agreement (“Amendment No. 1”) is made effective and entered into on December 21, 2020 (the “Amendment Effective Date”) by and between Siegfried Evionnaz SA, with principal offices located at Route du Simplon 1, 36, 1902 Evionnaz, Switzerland (together with its Affiliates and subsidiaries “Vendor”); and Keryx Biopharmaceuticals, Inc., with its offices at 245 First Street, Cambridge, Massachusetts, USA 02142 (“Keryx”).


WHEREAS, Vendor and Keryx entered into a Master Manufacturing Services and Supply Agreement dated December 20, 2017 (“Agreement”) under which Vendor manufactures Product for purchase by Keryx; and


WHEREAS, on December 12, 2018, Keryx merged with Akebia Therapeutics, Inc. (“Akebia”) and, pursuant to such merger, Akebia assumed all of Keryx’s rights and obligations under the Agreement. Keryx continues to operate as a wholly owned subsidiary of Akebia, and Akebia is an Affiliate of Keryx; and


WHEREAS, Vendor and Keryx wish to amend the Agreement as herein provided.


NOW THEREFORE, Vendor and Keryx hereto mutually agree as follows:


1.The text of Section 16.1 of the Agreement is be deleted and is hereby replaced by the following:


16.1    The term of this Agreement (the “Term”) shall commence as of the Agreement Date and, subject to earlier termination in accordance with the provisions of this Section 16, shall end on December 31, 2021.  Unless terminated by one of the Parties with at least eleven (11) months’ prior written notice to the other Party before the end of the original or renewal term then in effect, this Agreement shall automatically renew for subsequent terms of one (1) year.


2.For the purpose of this Amendment No. 1, the defined terms used herein shall have the same meaning as those used in the Agreement, unless otherwise specified in this Amendment No. 1.


3.Except as provided for in this Amendment No. 1, all other terms and conditions of the Agreement shall remain in full force and effect.


4.The governing law and jurisdiction applicable to the Agreement shall apply to this Amendment No. 1.




[Signature page follows]













        



IN WITNESS WHEREOF, Vendor and Keryx hereto have caused this Amendment No. 1 to be executed by their duly authorized representatives as of the date first above written.




Signed on behalf of Siegfried Evionnaz SA    Signed on behalf of Keryx Biopharmaceuticals, Inc.


By:    /s/ Marianne Spane_______            By:    /s/ Michel Dahan__________


Name:    Marianne Spane        ____            Name:    Michel Dahan_____________


Date:    21/12/2020____________            Date:    December 21, 2020        


Signed on behalf of Siegfried Evionnaz SA        
                


By:    /s/ Luca Parlanti                    
    
Name:    Luca Parlanti        ________            


Date:    21/12/2020_____________
tcon-ex1028_848.htm



Exhibit 10.28

Amendment #2

Cooperative Research and Development Agreement #12-1-00012

“Clinical Development of TRACON Pharmaceuticals, Inc.’s Compound TRC102 (methoxyamine HCl), a Small Molecule Inhibitor of Base Excision Repair, as an Anti-Cancer Agent”

The purpose of this amendment is to change certain terms of the above-referenced Cooperative Research and Development Agreement (CRADA).  These changes are reflected below, and except for these changes, all other provisions of the original CRADA remain in full force and effect.  Two originals of this amendment are provided for execution; one is to remain with the National Cancer Institute and the other is to remain with the Collaborator.

The aforementioned CRADA shall be amended as follows:


	
1.
	
The term of this CRADA is extended three (3) years such that the new expiration date is August 7, 2023.





	
2.
	
Dr. Fernanda Arnaldez is removed as NIH CRADA Extramural Investigators.  Dr. Charles Kunos is added as a NIH CRADA Extramural Investigator.




 

ACCEPTED AND AGREED TO:

For the National Cancer Institute

 

 


		
	
/s/ James H. Doroshow
	
January 8, 2021

	
James H. Doroshow, M.D.
	
Date

	
Deputy Director, NCI
	
 




 

For Tracon Pharmaceuticals:

 


		
	
/s/ Charles P. Theuer, M.D., Ph.D.
	
January 7, 2021

	
Charles P. Theuer, M.D., Ph.D.

President and CEO
	
Date
November 17, 1952

No. 56948.

#### Fuchs Shoe Corporation *v.*United States,

protests 173977-K, etc.

C. D. 1466. Motion of Government for rehearing denied.
Exhibit 32.1

                     Certification pursuant to Section 1350
      as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
      --------------------------------------------------------------------


In  connection  with  the  Quarterly  Report  of  DA Consulting Group, Inc. (the
"COMPANY")  on  Form 10-Q for the period ended September 30, 2003, as filed with
the  Securities  and  Exchange  Commission on the date hereof (the "REPORT"), I,
Virginia  L. Pierpont, Chief Executive Officer of the Company, certify, pursuant
to  18 U.S.C. Sec.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act  of  2002,  that:

1)     the Report fully complies with the requirements of Section 13(a) or 15(d)
of  the  Securities  Exchange  Act  of  1934,  as  amended;  and

2)     the  information contained in the Report fairly presents, in all material
respects,  the  financial  condition  and  results of operations of the Company.



                                          /s/  Virginia  L.  Pierpont
                                     -------------------------------------------
                                               Virginia  L.  Pierpont
                                        President  and  Chief  Executive Officer
                                           (Principal  Executive  Officer)
                                             Date:  November  14,  2003


A  signed  original  of  this written statement required by Section 906 has been
provided  to  DA  Consulting  Group,  Inc. and will be retained by DA Consulting
Group, Inc. and furnished to the Securities and Exchange Commission or its staff
upon  its  request.


<PAGE>
Before the Third Division,

March 12, 1947

No. 51611.

#### Protest 664719-G of T. Sumida & Co., Ltd. (Honolulu).

Opinion by

Cline, J.

It was stipulated that the bean flour is similar in all material respects to that the subject of *Togasaki*v. *United States*(23 C. C. P. A. 342, T. D. 48197). In accordance therewith the claim at 35 percent under paragraph 775 was sustained.
**AD Economic Evaluation**



### Docket No . FAA - 20 14 - 1058 Directorate ID : 20 14 - SW - 065 - AD Helicopter Model: Airbus Helicopters Model EC155B1 and AS 365 N3 Helicopters Number of Helicopters (U.S. Operators): 16 Helicopters in th e US Registry . Reason : The actions of this AD are intended prevent unpredictable and unexpected roll oscillations during coupled L ocalizer/Instrument L anding System or Very High Frequency Omnidirectional Range approaches. Costs : Parts per Helicopter None Labor per Helicopter ( One Half work- hour x 

### $ 8 5 /work - hour for the pen and - ink changes to the flight manual. ) $ 43

Other (Explain) Total Cost per Helicopter $ 43 Total US Fleet Cost $ 688 Executive Order 12866 : Could the AD be considered a “signifi cant regulatory action?” Yes ( ) No (  ) DOT Regulatory Policies and Procedures : Is the AD significant? Yes ( ) Explain Below No (  ) Regulatory Flexibility Act : Will the AD have a significant economic impact on a substantial number of small entiti es? Yes ( ) No (  ) Project Engineer : George Schwab
----

**Exhibit          32.2**

**CERTIFICATION      PURSUANT TO 18 U.S.C. SECTION 1350**

| (1) | the                Quarterly Report on Form 10-Q of the Company for the quarter ended                March                31, 2007 (the “Report”) fully complies with the requirements of Section                13(a) or 15(d) of the Securities Exchange Act of 1934;                and |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | the                information contained in the Report fairly presents, in all material                respects, the financial condition and results of operations of the                Company. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                             |                                                                                                                                                  |                                       |
|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|
| Dated:              May 15, 2007 |                                                                                                                                             | /s/               Christine A. Herren |
|                             | Christine              A. HerrenSenior Director and Controller              (PrincipalFinancial Officer and Principal              AccountingOfficer) |
EXHIBIT (10.8(ii))

AMENDMENT NO. 1 
TO THE 
ECOLAB MIRROR SAVINGS PLAN 
(As Amended and Restated effective as of January 1, 2014)
WHEREAS, Ecolab Inc. (the “Company”) has established and currently maintains the Ecolab Mirror Savings Plan (As Amended and Restated effective as of January 1, 2014) (the “Plan”); and
WHEREAS, the Company desires to amend the Plan to timely reflect proposed regulations under Section 162(m) of the Internal Revenue Code of 1986, as amended.
NOW, THEREFORE, pursuant to Section 5.1 of the Ecolab Inc. Administrative Document for Non-Qualified Benefit Plans (the “Administrative Document”) and subject to Section 7.1 of the Plan, the Company hereby amends the Plan as set forth below. Words used herein with initial capital letters that are defined in the Plan or the Administrative Document are used herein as so defined.
Section 7.4 is amended effective December 31, 2020, by adding the following sentence to the end thereof:
“Notwithstanding the foregoing, this Section 7.4 shall no longer apply effective December 31, 2020 to the extent this Section 7.4 is inconsistent with any proposed or final regulations issued under Code Section 162(m) or Code Section 409A and on which regulations the Company may reasonably rely as of the date of any potential application of this Section 7.4.”  
IN WITNESS WHEREOF, Ecolab Inc. has executed this Amendment No. 2 this 2nd day of December, 2020.
​
	​


	​


	​


	


	​
	​
	​
	ECOLAB INC.

	​
	​
	​
	​

	​
	​
	​
	​

	​
	​
	​
	/s/ Laurie M. Marsh

	​
	​
	​
	Laurie M. Marsh

	​
	​
	​
	Executive Vice President, Human Resources

	​
	​
	​
	​

	​
	​
	​
	​

	ATTEST:
	​
	​
	​

	​
	​
	​
	​

	​
	​
	​
	​

	/s/ Michael C. McCormick
	​
	​
	​

	Michael C. McCormick
	​
	​
	​

	Secretary
	​
	​
	​



​
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Research Education Program (R25 Clinical Trial Not Allowed).                    

*Date:*                         December 1, 2023.                    

*Time:*                         10:00 a.m. to 6:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G33, Rockville, MD 20892 (Virtual Meeting).                    

*Contact Person:*                         Poonam Pegu, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G33, Rockville, MD 20852, 240-292-0719,                         *poonam.pegu@nih.gov*.                    

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: November 3, 2023.

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-24708 Filed 11-7-23; 8:45 am]

BILLING CODE 4140-01-P
No. 64773.

#### Seaboard Import Co., Inc. *v.*United States,

protest 60/1540 (New York).

Opinion by

Oliver, C. J.

In accordance with stipulation of counsel that the merchandise consists of celluloid flowers similar in all material respects to those the subject of Abstract 59302, the claim of the plaintiff was sustained.
Volume by Transaction Type:

[August to September Change “1,527, 585,499,086
[Percentage Change “8.877%
[Grand Total - September 2015 4;345,155,745,308]
[Sept 2015 to Sept 2016 Change 11,335,009,214,885|

[Percentage Change

Dollar Amount] % of Total Dollar Amount] ‘Number of Transactions] __% of Total Number of Transactions|
[Fiduciary (investment & Borrowing) 15,557,884 261,806| 99.22% 3811 6.51%
leuv/Sell 115,539,297,687, 0.74% 339.473 32.49%
[eenefits (RITS) 5,659,499,853| 0.0884 484] 0.32%
[check Aftermath (TRACS) 71,900,843] 0.00% L033] 0.68%
[Zero Dollar 0 0.00% 1 0.00%
[Grand Total - September 2016 15,680,164, 960,188| 100.00%| 150,800 100.00%|
[Grand Total - August 2016 17,207,750,459,274] 100.00%| 321,888 '100.00%|
<Page>

                                                                        EX. 99.1

                      CHIEF EXECUTIVE OFFICER CERTIFICATION
                       PURSUANT TO 18 U.S.C. SECTION 1350

     In connection with the annual report of General Maritime Corporation (the
"Company") on Form 10-K for the period ending December 21, 2002, as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), the
undersigned Chief Executive Officer of the Company, hereby certifies pursuant to
18 U.S.C. Section 1350 that:

     (1)  The Report fully complies with the requirements of Section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     (2)  The information contained in the Report fairly presents, in all
          material respects, the financial condition and result of operations of
          the Company.

     This certification is made solely for the purposes of 18 U.S.C. Section
1350, and not for any other purpose.


/s/ Peter C. Georgiopoulos
--------------------------
Peter C. Georgiopoulos

Chairman, Chief Executive
Officer, and President
EXHIBIT 5  [LETTERHEAD OF SPROULE ASSOCIATES LIMITED]   CONSENT OF INDEPENDENT PETROLEUM ENGINEERS   We hereby consent to the use of
our name in the Annual Report on Form 40-F (the Annual Report) of Enerplus
Resources Fund (the Registrant).  We
hereby further consent to the inclusion in the Annual Report of the
Registrants Renewal Annual Information Form dated May 16, 2003 for the
year ended December 31, 2002, which document makes reference to our firm and
our report dated February 10, 2003 and effective January 1, 2003, evaluating
the Registrants oil, natural gas and natural gas liquids interests effective
January 1, 2003.  Calgary,
  Alberta, Canada
  May 16, 2003
  SPROULE
  ASSOCIATES LIMITED/s/ KEN H.
  CROWTHERKen H.
  CrowtherPresident
No. 54534.

#### D. C. Andrews & Co. *v.*United States,

protest 123242-K/12815-(New Orleans).

Opinion by

Cline, J.

In accordance with stipulation of counsel that the-merchandise consists of Edam process-cheese similar in all material respects to-that the subject of *Dutch Cheese Importers Co.*v. *United States*(23 Cust. Ct. 98, C. D. 1197), the claim of the plaintiff was sustained.
<PAGE>


 Exhibit 99

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the accompanying quarterly report of The Lionshare
Group, Inc. (the "Company") on Form 10-QSB for the period ending December 31,
2002, as filed with the Securities and Exchange commission on the date hereof
(the "Report"), I, Jeff Barocas, principal executive officer and principal
accounting officer of the Company, certify, pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the
best of my knowledge, that:

          (1) The Report fully complies with the  requirements  of Section 13(a)
     or 15(d) of the Securities Exchange Act of 1934; and

          (2) The  information  contained in the Report fully  presents,  in all
     material respects, the financial condition and results of operations of the
     Company.


         By:      /s/Jeff Barocas
                  ---------------------
                  Jeff Barocas

                  February 18, 2003

<PAGE>
<Page>

INDEPENDENT AUDITORS' CONSENT

We consent to the use in this Post-Effective Amendment No. 2 to Registration
Statement No. 333-102628 of Hartford Life and Annuity Insurance Company
Separate Account Three on Form N-4, of our report dated March 26, 2003 of
Hartford Life and Annuity Insurance Company relating to the statutory
financial statements as of and for the year ended December 31, 2002 and of
our report dated February 21, 2003 of Hartford Life and Annuity Insurance
Company Separate Account Three relating to the financial statements as of and
for the year ended December 31, 2002, appearing in the Statement of
Additional Information, which is a part of such Registration Statement, and
to the reference to us under the headings "Experts" in such Statement of
Additional Information.

Deloitte & Touche LLP
Hartford, Connecticut
October 6, 2003